Skip to main content
. Author manuscript; available in PMC: 2015 Oct 15.
Published in final edited form as: Cancer Res. 2014 Aug 27;74(20):5723–5733. doi: 10.1158/0008-5472.CAN-13-2347

Figure 6. Tumor-bearing mice treated with mAbs to HMGB1 or with A Box have reduced levels of MDSC.

Figure 6

A, C57BL/6 and BALB/c mice were inoculated s.c. with 5 x 105 MC38 colon carcinoma cells or in the mammary fat pad with 7 x 103 4T1 mammary carcinoma cells, respectively. Mice were given recombinant A box (300μg/mouse) or vehicle (PBS) three times per week starting when tumors were first palpable (day 7-9 post inoculation). p values were obtained by log rank test. B, C57BL/6 mice were inoculated as in panel A. Treatment with 2G7 (5μg/200μl/mouse, 3x/week), irrelevant IgG, or A Box was started on day 10-13 when tumors were first palpable. Treatment was terminated on day 45 and blood leukocytes were analyzed by flow cytometry for total (Gr1+CD11b+), monocytic (MO; CD11b+Ly6G-Ly6C+), and granulocytic (PMN; CD11b+Ly6G+Ly6C−) MDSC. Mice were sacrificed on day 50 when their tumors were approximately the same size, and spleen and tumor-infiltrating leukocytes (CD45+ cells) were analyzed by flow cytometry. n = 7 (blood, control-treated for 2G7), 4 (A Box, PBS-treated), 6 (tumor-infiltrating and spleen, control-treated; blood, 2G7-treated), 4 (tumor-infiltrating and spleen, 2G7-treated), and 4 (A Box-treated) mice/group. Data for 2G7 and their control-treated mice are pooled from two independent experiments; data for A Box and their control-treated mice are from a single experiment.